Abivax appoints Marc de Garidel as CEO

6 April 2023

French clinical-stage biotech Abivax (Euronext Paris: ABVX) has appointed Marc de Garidel as chief executive (CEO) and interim board chairman of the company, effective May 5, 2023.

Corinna zur Bonsen-Thomas will step down as acting chair, a position she has held since August 2022, and will remain a board member. Prof Hartmut Ehrlich will retire from the CEO position, which he has held since the company’s founding in 2013, but will remain as a strategic advisor until the transition is complete. The company expects to appoint a long-term board chairman in 2023.

Abivax noted that Mr de Garidel has an outstanding track record in the pharmaceutical and biotechnology sector and as a CEO for the last 12 years. He has led the successful sale of CinCor Pharma for up to $1.8 billion, subject to the achievement of certain milestones, to AstraZeneca (LSE: AZN) in February 2023, after joining the firm in July 2021. Mr de Garidel also sold Corvidia Therapeutics in August 2020 to Novo Nordisk (NOV: N) for $2.1 billion in total consideration after having joined the company in April 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK